Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2003

View Archived Issues

Inhibitors of MraY transferase as potential new antibacterial agents

SSR-591813, a partial alpha4beta2 nAChR agonist, effective in animal models of nicotine dependence

Safety, tolerability and pharmacokinetics of CHF-3381 in healthy volunteers

The neuroprotective agent TV-3326 improves cognitive tasks

Gamma-tocotrienol: a natural vitamin E homologue with natriuretic function

New gene therapy platform to treat focal seizure disorders

Topical TMC-120, a NNRTI, inhibits vaginal transmission of HIV-1 in hu-SCID mice

In vitro anti-HIV-1 activity of leflunomide reported by U. of Zurich researchers

AM-1241 reverses neuropathic pain in rats via activation of CB2 receptors

Potent activities of 1beta-methylcarbapenems against multiresistant Gram-positive bacteria

A new 5-HT2A receptor antagonist with high selectivity and potent efficacy

Expert guidelines established for the management of postoperative nausea and vomiting

ATL-1102 enters phase I trial for MS

BMS and Flamel enter Basulin agreement

Orphan drug designation for glioma drug 131I-TM-601

BioCryst ends collaboration with 3-Dimensional Pharmaceuticals

Another series of herpesvirus DNA polymerase inhibitors presented by Pharmacia

Novel chemokine CCR4 receptor modulators and their use in asthma therapy

Arena patent covers 5-HT2A receptor modulators for psychosis, platelet aggregation, asthma, etc.

New tyrosine kinase inhibitors in early development at Novartis

Indian researchers describe new triazole-based antibacterial agents

Novel p56lck inhibitors described with potent activity against T-cell proliferation

Procter & Gamble claims CRF2 agonists with utility in muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...